GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Cyclically Adjusted PS Ratio

Exact Sciences (Exact Sciences) Cyclically Adjusted PS Ratio : 8.40 (As of Apr. 28, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Exact Sciences's current share price is $58.85. Exact Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $7.01. Exact Sciences's Cyclically Adjusted PS Ratio for today is 8.40.

The historical rank and industry rank for Exact Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

EXAS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.01   Med: 73.51   Max: 273
Current: 8.4

During the past years, Exact Sciences's highest Cyclically Adjusted PS Ratio was 273.00. The lowest was 6.01. And the median was 73.51.

EXAS's Cyclically Adjusted PS Ratio is ranked worse than
85.93% of 135 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.21 vs EXAS: 8.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exact Sciences's adjusted revenue per share data for the three months ended in Dec. 2023 was $3.571. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.01 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exact Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Exact Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cyclically Adjusted PS Ratio Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.62 51.03 20.07 9.21 10.56

Exact Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.21 11.66 15.04 10.25 10.56

Competitive Comparison of Exact Sciences's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Exact Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Cyclically Adjusted PS Ratio falls into.



Exact Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Exact Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=58.85/7.01
=8.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Exact Sciences's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.571/129.4194*129.4194
=3.571

Current CPI (Dec. 2023) = 129.4194.

Exact Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.004 99.695 0.005
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.018 99.070 0.024
201503 0.048 99.621 0.062
201506 0.091 100.684 0.117
201509 0.134 100.392 0.173
201512 0.150 99.792 0.195
201603 0.153 100.470 0.197
201606 0.216 101.688 0.275
201609 0.268 101.861 0.341
201612 0.322 101.863 0.409
201703 0.437 102.862 0.550
201706 0.511 103.349 0.640
201709 0.609 104.136 0.757
201712 0.728 104.011 0.906
201803 0.746 105.290 0.917
201806 0.843 106.317 1.026
201809 0.964 106.507 1.171
201812 1.163 105.998 1.420
201903 1.284 107.251 1.549
201906 1.547 108.070 1.853
201909 1.689 108.329 2.018
201912 2.111 108.420 2.520
202003 2.348 108.902 2.790
202006 1.796 108.767 2.137
202009 2.720 109.815 3.206
202012 2.980 109.897 3.509
202103 2.373 111.754 2.748
202106 2.535 114.631 2.862
202109 2.654 115.734 2.968
202112 2.747 117.630 3.022
202203 2.790 121.301 2.977
202206 2.958 125.017 3.062
202209 2.955 125.227 3.054
202212 3.114 125.222 3.218
202303 3.374 127.348 3.429
202306 3.452 128.729 3.471
202309 3.413 129.860 3.401
202312 3.571 129.419 3.571

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exact Sciences  (NAS:EXAS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Exact Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (Exact Sciences) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Executives
Brian Baranick officer: Gen. Mgr., Precision Oncology 441 CHARMANY DRIVE, MADISON WI 53719
Sarah Condella officer: SVP, Human Resources 441 CHARMANY DRIVE, MADISON WI 53719
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Everett Cunningham officer: Chief Commercial Officer C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeffrey Thomas Elliott officer: Chief Financial Officer 5505 ENDEAVOR LANE, MADISON WI 53719
James Edward Doyle director 5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott officer: General Counsel 5505 ENDEAVOR LANE, MADISON WI 53719
Katherine S Zanotti director 431 E 9TH STREET, HINSDALE IL 60521
Jacob A Orville officer: General Manager, New Ventures 5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy director, officer: Vice President 5505 ENDEAVOR LANE, MADISON WI 53719
D Scott Coward officer: SVP and General Counsel 441 CHARMANY DRIVE, MADISON WI 53719
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard officer: SVP, Chief Scientific Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Torsten Hoof officer: General Manager, International 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063

Exact Sciences (Exact Sciences) Headlines

From GuruFocus